Johnson & Johnson is making another decisive move, announcing plans to spin off its orthopedics business, DePuy Synthes, within the next two years. This strategic divestiture, following the successful Kenvue consumer health spinoff, aims to streamline J&J’s portfolio, turbocharge growth in high-margin sectors like oncology and immunology, and potentially unlock greater value for shareholders. Accompanied by robust Q3 earnings and an optimistic 2025 outlook, this pivot signals a new era for the healthcare giant, focusing on innovation and market leadership.
In a significant strategic realignment, Johnson & Johnson (J&J) revealed plans to separate its orthopedics business, to be named DePuy Synthes, into a standalone company within the next 18 to 24 months. This announcement, made alongside strong third-quarter earnings, marks J&J’s second major spinoff in two years, underscoring a clear intent to intensify its focus on higher-growth healthcare segments.
For long-term investors, this isn’t just news; it’s a blueprint for J&J’s future. The company is actively shedding lower-growth divisions to concentrate capital and innovation on areas promising greater returns and competitive advantage, such as pharmaceuticals and advanced medical technologies.
The Orthopedics Divestment: A Strategic Clear-Out
The decision to spin off DePuy Synthes follows a 2023 restructuring program for the orthopedics business, where J&J aimed to exit certain markets and discontinue some products. Generating approximately $9.2 billion last year, this unit accounted for about 10% of J&J’s total revenue. While profitable, the orthopedics division represented roughly 30% of J&J’s MedTech segment but was growing at a pace below the rest of the portfolio.
J&J Chief Financial Officer Joe Wolk articulated the company’s view, stating that the next phase of innovation in orthopedics was “beyond our scope and probably in better hands somewhere else.” This indicates a recognition that while orthopedics is a vital field, J&J believes its resources are better allocated to areas where it can achieve more substantial growth and higher margins. The new standalone company, DePuy Synthes, will be helmed by industry veteran Namal Nawana, signaling an intent for focused leadership to drive its future.
A Pattern of Portfolio Streamlining
This isn’t J&J’s first major portfolio adjustment. The company recently spun off its $15 billion consumer health unit into Kenvue in 2023, a move that created an independent public company for household brands like Tylenol and Band-Aid. This earlier divestiture set a precedent for J&J’s strategy to streamline operations and enhance focus on its core pharmaceutical and medical technology segments. Investors who observed the rationale behind the Kenvue separation will recognize a similar strategic logic at play with the orthopedics spinoff, as reported by Reuters.
J&J’s Sharpened Focus and Growth Projections
Post-spinoff, J&J aims to concentrate on high-growth, high-margin areas. These include pivotal segments such as oncology, immunology, neuroscience, surgery, vision care, and cardiovascular products. This strategic pivot is expected to significantly enhance J&J’s overall growth trajectory. J.P. Morgan analysts echoed this sentiment, suggesting the planned spin-off “should create a faster-growing J&J over time” by optimizing its MedTech segment.
The company has laid out optimistic financial expectations for 2026, projecting total revenue growth to exceed 5%, surpassing current analysts’ estimates of 4.6%. Additionally, adjusted earnings are expected to top Wall Street estimates of $11.39 per share by as much as 5 cents. These projections are bolstered by anticipated new drug launches and a strengthened medical devices portfolio.
Q3 Earnings Beat: A Strong Backdrop for Change
The orthopedics spinoff announcement was made against a backdrop of impressive third-quarter financial results for J&J. The company reported adjusted earnings of $2.80 per share, exceeding analysts’ expectations by 4 cents. Third-quarter sales reached $23.99 billion, narrowly beating Wall Street estimates of $23.75 billion, according to LSEG data.
Key highlights from the earnings report include:
- Pharmaceuticals Sales: Jumped 6.8% year-over-year to $15.56 billion, slightly outpacing estimates.
- Darzalex: The blood cancer treatment generated $3.67 billion in sales, largely in line with forecasts.
- Stelara: Maintained its strength with $1.5 billion in sales, even after surpassing its patent cliff.
- Tremfya: Showcased significant growth, with sales soaring 40% to $1.4 billion. J&J expressed strong confidence in its future potential, with estimated peak sales reaching $10 billion.
- Medical Device Sales: Also rose 6.8% to $8.43 billion, primarily driven by electrophysiology products.
Looking ahead, J&J raised its 2025 product revenue forecast to between $93.5 billion and $93.9 billion, an increase of about $300 million from its previous view and above analysts’ expectations. This positive financial performance provides a solid foundation for the significant strategic changes underway. Further details on J&J’s financial performance can be found on its official investor relations pages.
Investor Sentiment and Long-Term Outlook
While the strategic benefits are clear, some investors voice valid concerns. Brian Mulberry, portfolio manager at Zacks Investment Management, noted that spinning off a division contributing 10% of revenue is a “fairly large strategic pivot,” highlighting potential near-term uncertainties. However, the long-term perspective from analysts like J.P. Morgan suggests that J&J is positioning itself as “one of the cleaner stories” among large healthcare companies, moving past challenges like Stelara’s loss of exclusivity to benefit from steady growth in its core portfolio.
J&J’s shares initially saw a slight dip of 1.2% in early trading following the announcement, though they are up 32% year-to-date, outperforming the broader S&P Healthcare Index’s 3% rise. This suggests underlying investor confidence in J&J’s strategic direction. CFO Wolk confirmed that the separation process is already in motion, with further material updates anticipated in mid-2026. The company’s primary focus for the separation is a tax-free spinoff, though other options remain open.
The divestiture of the orthopedics unit, much like the Kenvue spinoff, reflects J&J’s commitment to creating a more agile, high-growth enterprise. For long-term shareholders, this means a leaner, more focused company with amplified potential in its most innovative and profitable sectors. While the transition may present short-term fluctuations, the strategic clarity and robust financial performance paint a compelling picture for sustained growth and value creation.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence or consult with a qualified financial advisor before making investment decisions.
